April 23, 2021
Health News

A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population – Medical Xpress

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterolthe so-called “bad” cholesterolby 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…

Click here to view the original article.

Related Posts

You might also like ...

Article feature image
Wisconsin Center accepting walk-ins for vaccine, ample supply – WISN Milwaukee
Article feature image
Health officials monitoring rise of COVID-19 cases in NH, race to vaccinate continues – WMUR Manchester
Article feature image
Wisconsin reaches 3.5 million “shots in the arm” milestone, fewer than 600 new COVID-19 cases confirmed Sunday – WSAW